Ken Griffin Astria Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 100 shares of ATXS stock, worth $681. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100

Previous 5,700 98.25%

Holding current value

$681

Previous $62,000 100.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$8.81 - $12.1 $1.24 Million - $1.71 Million	141,225 Added 17.86%	931,979 $8.21 Million
Q3 2024 Nov 14, 2024	SELL	$8.97 - $12.65 $5.59 Million - $7.89 Million	-623,587 Reduced 44.09%	790,754 $8.71 Million
Q2 2024 Aug 14, 2024	BUY	$8.83 - $13.51 $4.73 Million - $7.24 Million	536,190 Added 61.06%	1,414,341 $12.9 Million
Q1 2024 May 15, 2024	BUY	$6.99 - $16.69 $5.13 Million - $12.3 Million	734,493 Added 511.28%	878,151 $12.4 Million
Q4 2023 Feb 14, 2024	BUY	$4.42 - $8.06 $540,163 - $985,004	122,209 Added 569.77%	143,658 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$6.89 - $9.86 $144,786 - $207,198	21,014 Added 4830.8%	21,449 $160,000
Q2 2023 Aug 14, 2023	SELL	$8.33 - $13.72 $152,847 - $251,748	-18,349 Reduced 97.68%	435 $3,000
Q1 2023 May 15, 2023	SELL	$11.2 - $15.79 $1.35 Million - $1.9 Million	-120,562 Reduced 86.52%	18,784 $249,000
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $125,512 - $251,194	16,870 Added 13.77%	139,346 $2.07 Million
Q3 2022 Nov 14, 2022	SELL	$2.97 - $10.34 $289,533 - $1.01 Million	-97,486 Reduced 44.32%	122,476 $1.11 Million

Others Institutions Holding ATXS

# of Institutions

115

Shares Held

50.3M

Call Options Held

75K

Put Options Held

6.2K

View Full List

About Astria Therapeutics, Inc.

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $103M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

More about ATXS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account